Literature DB >> 14608525

Elevated intracardiac angiotensin II leads to cardiac hypertrophy and mechanical dysfunction in normotensive mice.

Catherine E Huggins1, Andrea A Domenighetti, Thierry Pedrazzini, Salvatore Pepe, Lea M D Delbridge.   

Abstract

INTRODUCTION: Angiotensin II (Ang II) is known to induce cardiac growth and modulate myocardial contractility. It has been reported that elevated levels of endogenous Ang II contribute to the development of cardiac hypertrophy in hypertensives. However, the long-term functional effects of cardiac exposure to Ang II in normotensives is unclear. A recently developed transgenic mouse (TG1306/1R), in which cardiac-specific overproduction of Ang II produces primary hypertrophy, provides a new experimental model for investigation of this phenotype. The aim of the present study was to use this model to investigate whether there is a functional deficit in primary hypertrophy that may predispose to cardiac failure and sudden death. We hypothesised that primary cardiac hypertrophy is associated with mechanical dysfunction in the basal state.
METHODS: Normotensive heterozygous TG1306/1R mice harbouring multiple copies of a cardiac-specific rat angiotensinogen gene1 were studied at age 30-40 weeks and compared with age-matched wild-type littermates. Left ventricular function was measured ex vivo in bicarbonate buffer-perfused, Langendorff- mounted hearts (at a perfusion pressure of 80 mmHg, 37 degrees C) using a fluid-filled PVC balloon interfaced to a pressure transducer and digital data acquisition system.
RESULTS: There was no difference in the mean (+SEM) intrinsic heart rate of TG1306/1R and wild-type control mice (357.4 +/- 11.8 vs. 367.5 +/- 20.9 bpm, n=9 &amp; 7). Under standardised end-diastolic pressure conditions, TG1306/1R hearts exhibited a significant reduction in peak developed pressure (132.2 +/- 9.4 vs. 161.5 +/- 3.1 mmHg, n=9 &amp; 7, p<0.05) and maximum rate of pressure development (3566.7 +/- 323.7 vs. 4486.3 +/- 109.4 mmHg, n=9 &amp; 7, p<0.05). TG1306/1R mice show a significant correlation between incidence of arrhythmia and increasing heart size (Spearman s correlation coefficient 0.61).
CONCLUSION: These data demonstrate that chronic in vivo exposure to elevated levels of intra-cardiac Ang II is associated with significant contractile abnormalities evident in the ex vivo intact heart. Our findings suggest that endogenous overproduction of cardiac Ang II, independent of changes in blood pressure, is sufficient to induce ventricular remodelling that culminates in impaired cardiac function which may precede failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14608525     DOI: 10.3317/jraas.2003.030

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  11 in total

1.  Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB.

Authors:  Yewei Ma; Liping Zhang; Tao Peng; Jizhong Cheng; Shilpa Taneja; Jiqiang Zhang; Patrice Delafontaine; Jie Du
Journal:  Endocrinology       Date:  2005-12-01       Impact factor: 4.736

2.  Ageing-related cardiomyocyte functional decline is sex and angiotensin II dependent.

Authors:  Kimberley M Mellor; Claire L Curl; Chanchal Chandramouli; Thierry Pedrazzini; Igor R Wendt; Lea M D Delbridge
Journal:  Age (Dordr)       Date:  2014-02-25

3.  Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling.

Authors:  Yumei Zhan; Courtney Brown; Elizabeth Maynard; Aleksandra Anshelevich; Weihua Ni; I-Cheng Ho; Peter Oettgen
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

4.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557

5.  Interactive roles of NPR1 gene-dosage and salt diets on cardiac angiotensin II, aldosterone and pro-inflammatory cytokines levels in mutant mice.

Authors:  Di Zhao; Subhankar Das; Kailash N Pandey
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

Review 6.  The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions.

Authors:  Amedeo Tirandi; Federico Carbone; Fabrizio Montecucco; Luca Liberale
Journal:  Eur J Clin Invest       Date:  2021-11-08       Impact factor: 5.722

7.  Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor.

Authors:  Peter Moritz Becher; Svenja Hinrichs; Nina Fluschnik; Jan K Hennigs; Karin Klingel; Stefan Blankenberg; Dirk Westermann; Diana Lindner
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

8.  Protective effects of methylsulfonylmethane on hemodynamics and oxidative stress in monocrotaline-induced pulmonary hypertensive rats.

Authors:  Sadollah Mohammadi; Moslem Najafi; Hossein Hamzeiy; Nasrin Maleki-Dizaji; Masoud Pezeshkian; Homayon Sadeghi-Bazargani; Masoud Darabi; Sara Mostafalou; Shahab Bohlooli; Alireza Garjani
Journal:  Adv Pharmacol Sci       Date:  2012-10-15

9.  Local Application of Leptin Antagonist Attenuates Angiotensin II-Induced Ascending Aortic Aneurysm and Cardiac Remodeling.

Authors:  Danny Ben-Zvi; Naphtali Savion; Frank Kolodgie; Amos Simon; Sudeshna Fisch; Katrin Schäfer; Noa Bachner-Hinenzon; Xin Cao; Arieh Gertler; Gili Solomon; Erez Kachel; Ehud Raanani; Jacob Lavee; Shlomo Kotev Emeth; Renu Virmani; Frederick J Schoen; Jacob Schneiderman
Journal:  J Am Heart Assoc       Date:  2016-05-03       Impact factor: 5.501

10.  Angiotensin II Induced Cardiac Dysfunction on a Chip.

Authors:  Renita E Horton; Moran Yadid; Megan L McCain; Sean P Sheehy; Francesco S Pasqualini; Sung-Jin Park; Alexander Cho; Patrick Campbell; Kevin Kit Parker
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.